Online citations, reference lists, and bibliographies.
← Back to Search

Diffuse Malignant Mesothelioma Of The Pleura In Ontario And Quebec: A Retrospective Study Of 332 Patients.

P. Ruffié, R. Feld, S. Minkin, Y. Cormier, A. Boutan-Laroze, R. Ginsberg, J. Ayoub, F. Shepherd, W. Evans, A. Figueredo
Published 1989 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Three-hundred thirty-two cases of pleural diffuse malignant mesothelioma (DMM) seen at large centers in Ontario and Quebec from 1965 to 1984 were reviewed retrospectively. Previous asbestos exposure was found in 44% of patients. Diagnosis was most often made by exploratory thoracotomy; pleural biopsy or cytology were rarely contributory. The delay in diagnosis was often long (median time, 3.5 months) and thrombocytosis (platelets greater than or equal to 400,000/microL) was common (41% of cases). The median survival (MS) was only 9 months. Eleven clinical variables were analyzed for prognostic significance. The three most important prognostic factors using a univariate analysis were stage, weight loss, and histologic type. For 118 patients with complete data, multivariate analysis showed that the stage of disease, high platelet count, and asbestos exposure were the most important prognostic factors. There was no cure of DMM, and we did not find any drastic differences in survival among groups of patients subjected to the different therapeutic measures. Radical surgery and radiotherapy were ineffective and we confirmed the low response rate to chemotherapeutic agents. This large retrospective trial can serve as a baseline for future studies in this field. In particular, it provides the basis for appropriate stratification variables to be used in future therapeutic trials.
This paper references
10.1002/1097-0142(19850501)55:9<1968::AID-CNCR2820550923>3.0.CO;2-9
Malignant mesothelioma secondary to chronic inflammation and old scars. Two new cases and review of the literature
G. Hillerdal (1985)
10.1136/thx.38.10.744
Evidence for longer survival of patients with pleural mesothelioma without asbestos exposure.
M. Law (1983)
Treatment of diffuse malignant mesothelioma: a review.
A. Chahinian (1978)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
10.1016/0007-0971(76)90039-5
Distant visceral metastases in pleural mesothelioma.
G. H. Roberts (1976)
10.1080/00039896.1978.10667302
Mesothelioma and asbestos in the Province of Quebec, 1969-1972.
G. Thériault (1978)
10.1378/CHEST.60.6.564
Diffuse malignant mesothelioma of the pleura: a review of 37 cases.
H. Oels (1971)
10.1016/S0003-4975(10)64593-6
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
M. Davalle (1986)
Malignant mesothelioma of pleura: clinicopathologic observation.
F. Jara (1977)
10.1164/ARRD.1984.129.5.754
Mortality among employees of an Ontario asbestos-cement factory.
M. Finkelstein (1984)
10.1001/JAMA.252.1.91
Landmark article April 6, 1964: Asbestos exposure and neoplasia. By Irving J. Selikoff, Jacob Churg, and E. Cuyler Hammond.
I. Selikoff (1984)
10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
10.1136/thx.36.9.669
Non-malignant asbestos pleural disease.
G. Hillerdal (1981)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1002/1097-0142(19850201)55:3<672::AID-CNCR2820550333>3.0.CO;2-Z
Malignant mesothelioma in British Columbia in 1982
A. Churg (1985)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
10.1177/030089168106700401
Histological Typing of Lung Tumours 1
E. Chaves (1981)
Malignant mesothelioma--clinical and epidemiological features. A report of 80 cases.
K. Solomons (1984)
10.5694/j.1326-5377.1985.tb122909.x
Trends in mortality from malignant mesothelioma of the pleura, and production and use of asbestos in Australia
Z. Xu (1985)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1002/1097-0142(19850301)55:5<1056::AID-CNCR2820550522>3.0.CO;2-V
Association of lymphocytic neoplasia and mesothelioma
A. Efremidis (1985)
10.1016/0002-9343(80)90103-5
Multimodality therapy for malignant mesothelioma based on a study of natural history.
K. H. Antman (1980)
Thrombocytose et cancer bronchique. A propos d'une série de 164 cancers broncho-pulmonaires.
G. Bouvenot (1979)
10.1002/AJIM.4700030407
Features of asbestos-exposed and unexposed mesothelioma.
A. Hirsch (1982)
10.5555/URI:PII:0093775481900439
Chemotherapy in the treatment of malignant mesothelioma.
J. Aisner (1981)
The significance of thrombocytosis in patients with carcinoma of the lung.
W. Diehl (1983)
10.1136/thx.39.11.872
Pleural mesothelioma and the syndrome of inappropriate secretion of antidiuretic hormone.
N. Siafakas (1984)
Le mésothéliome pleural malin: aspects cliniques et résultats du traitement
P. Leblanc (1984)
10.1111/j.1749-6632.1965.tb41141.x
HISTOLOGICAL CHARACTERISTICS OF MESOTHELIOMA ASSOCIATED WITH ASBESTOS *
J. Churg (1965)
10.1016/0091-7435(77)90025-1
Epidemiology of mesothelioma from estimated incidence.
J. C. Mcdonald (1977)
10.1136/thx.19.3.268
The Pathology of Mesotheliomata and an Analysis of their Association with Asbestos Exposure
D. Hourihane (1964)
10.1001/JAMA.1970.03170110058017
Thrombocytosis in patients with lung cancer.
S. Silvis (1970)
10.1002/1097-0142(19801001)46:7<1650::AID-CNCR2820460726>3.0.CO;2-Y
Malignant mesothelioma in North America
A. Mcdonald (1980)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1016/S0022-5223(19)40189-X
Malignant pleural mesothelioma. Report of 19 cases.
J. Shearin (1976)
10.1093/BIOMET/57.3.579
A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship
N. Breslow (1970)
Evaluation of survival data and two new rank order statistics arising in its consideration.
N. Mantel (1966)
10.1007/978-1-4612-4380-9_37
Regression Models and Life-Tables
D. Cox (1972)
10.1001/JAMA.1968.03140150010003
Asbestos exposure, smoking, and neoplasia.
I. Selikoff (1968)
10.5555/URI:PII:0093775481900403
Clinical presentation and natural history of benign and malignant mesothelioma.
K. Antman (1981)
10.1159/000206719
Thrombocytosis and microthrombocytosis: a clinical evaluation of 372 cases.
G. Robbins (1983)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1378/CHEST.64.5.641
Mesothelioma following exposure to asbestos: a review of 72 cases.
M. Borow (1973)
10.1200/JCO.1983.1.11.695
Malignant mesothelioma following radiation exposure.
K. H. Antman (1983)
Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.
G. Mårtensson (1984)
The role of surgery in diffuse malignant mesothelioma of the pleura.
E. Butchart (1981)
10.1136/thx.39.4.255
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
M. Law (1984)
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma.
A. Chahinian (1984)
Manifestations sanguines et médullaires dans les carcinomes bronchiques primitifs.
R. Piéron (1980)
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
P. Sørensen (1985)
10.1136/thx.37.11.810
Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour.
M. Law (1982)
10.1038/bjc.1985.105
Trend and distribution of mesothelioma in Denmark.
M. Andersson (1985)
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
M. Law (1984)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1200/JCO.1983.1.6.386
Peritoneal mesothelioma: natural history and response to chemotherapy.
K. H. Antman (1983)
10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
10.1164/ARRD.1978.117.4.789
Mesothelioma associated with the syndrome of inappropriate secretion of antidiuretic hormone.
W. Perks (1978)
Malignant mesothelioma; epidemiologic patterns in New York State.
N. Vianna (1981)
10.1136/oem.42.1.12
Combined effect of asbestos and smoking on mortality from lung cancer and mesothelioma in factory workers.
G. Berry (1985)
10.1016/0007-0971(83)90068-2
Malignant mesothelioma 1982: review of 4710 published cases.
G. Hillerdal (1983)
10.1002/1097-0142(19820601)49:11<2431::AID-CNCR2820491134>3.0.CO;2-W
Malignant mesothelioma of the pleura: Review of 123 patients
J. Brenner (1982)
10.1016/S0140-6736(83)91618-5
SIGNIFICANCE OF THROMBOCYTOSIS
G. Corbett (1983)
10.1007/BF01267847
Pleura mesothelioma and exposure to asbestos
R. Zielhuis (1975)
10.1001/ARCHINTE.1964.03860100079008
THROMBOCYTOSIS ASSOCIATED WITH MALIGNANT DISEASE.
J. Levin (1964)
10.1136/oem.41.4.514
Histological types of malignant mesothelioma and asbestos exposure.
W. Wright (1984)
Transplantation of human malignant mesothelioma into nude mice.
A. Chahinian (1980)
10.1002/1097-0142(19810601)47:11<2678::AID-CNCR2820471126>3.0.CO;2-9
Solitary fibrous tumors of the pleura: Eight new cases and review of 360 cases in the literature
M. Briselli (1981)
10.1002/1097-0142(197810)42:4<1692::AID-CNCR2820420406>3.0.CO;2-Y
The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma
B. S. Yap (1978)
10.1002/1097-0142(197010)26:4<914::AID-CNCR2820260427>3.0.CO;2-H
Epidemiology of primary malignant mesothelial tumors in canada
A. McDonald (1970)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1038/bjc.1982.168
Mortality from mesothelioma of the pleura during 1968-78 in England and Wales.
M. Gardner (1982)



This paper is referenced by
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
Matthew Wu (2015)
10.1055/s-2008-1081279
Mediastinal, hilar, and pleural image-guided biopsy: current practice and techniques.
K. Ahrar (2008)
10.1007/s11864-008-0070-4
Diagnosis, Staging, and Surgical Treatment of Malignant Pleural Mesothelioma
M. Kent (2008)
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma
S. V. Rutha (2002)
10.1378/CHEST.112.4_SUPPLEMENT.272S
Multimodality therapy for malignant pleural mesothelioma.
D. Sugarbaker (1997)
10.1002/PATH.1711720304
Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA)
M. Ramael (1994)
10.1183/09031936.94.07061029
Prognostic factors in malignant mesothelioma: where do we go from here?
J. Meerbeeck (1994)
10.1016/j.ijsu.2008.04.004
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
10.1097/00005382-200207000-00003
Occupational and Environmental Thoracic Malignancies
E. Gottschall (2002)
10.1007/s11912-011-0177-9
Malignant Pleural Mesothelioma
S. Raja (2011)
10.1136/thx.2007.090001a
Pulmonary puzzle
(2008)
Haematologic Paraneoplastic Syndromes in Pleural Mesothelioma: A Report of Two Cases and Review of the Literature
D. Doval (2009)
10.1164/RCCM.200312-1683OC
Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells.
F. Ebstein (2004)
10.1007/0-387-28274-2_21
Malignant Mesothelioma Following Radiation
K. Crew (2005)
10.1007/3-540-27329-8_8
Invasive Diagnostik und chirurgische Therapie
H. Dienemann (2005)
10.1046/j.1365-2303.2000.00211.x
Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis
A. Dejmek (2000)
10.1053/j.semtcvs.2009.07.002
Recent advances in mesothelioma staging.
W. Richards (2009)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
Angiogenesis, cyclooxygenase-2 and matrix metalloproteinases in malignant mesothelioma
J. Edwards (2003)
10.1038/bjc.1998.150
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
T. Nakano (1998)
10.1016/J.CURRPROBLCANCER.2004.04.001
Malignant pleural mesothelioma.
H. I. Pass (1993)
10.14789/PJMJ.52.319
Epidemiology of Mesothelioma related with Asbestos
Y. Inaba (2006)
10.1016/J.ANNDIAGPATH.2006.06.012
Mesothelioma in patients with nonoccupational asbestos exposure. An evidence-based approach to causation assessment.
A. Marchevsky (2006)
10.1016/S1010-7940(97)00191-7
Experimental assessment of photodynamic therapy with chlorins for malignant mesothelioma.
H. Ris (1997)
10.1055/S-2006-932132
[Comparison of patterns of metastasis between malignant pleural mesotheliomas and pulmonary carcinomas].
M. Scharmach (2006)
10.1136/bmjopen-2015-010589
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
N. Bayman (2016)
10.1200/JCO.1996.14.3.878
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
P. Soulié (1996)
1. PALLIATIVE SURGERY FOR TIiORACIC MALIGNANCIES
K. Yeh (1995)
10.1586/14737140.8.2.293
Current concepts in malignant pleural mesothelioma
A. Kaufman (2008)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.3310/HTA11010
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Y. Dundar (2007)
10.21037/tlcr.2018.07.06
Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?
Paul Halford (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar